You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced Stage, Aggressive Histology Non-Hodgkin's Lymphoma

Version: 2 ID: 6-7 Version 2 Jun 2013
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
T. Kouroukis, G. Browman, R. Meyer , Hematology Disease Site Group

Patient Population

Patients older than age 60 who have newly diagnosed, advanced-stage, aggressive histology non-Hodgkin’s lymphoma, an Eastern Cooperative Oncology Group (ECOG) performance status of less than 4 and no significant comorbid illnesses.

Intended Guideline Users

Hematologists and oncologists treating patients older than age 60 who have newly diagnosed, advanced-stage, aggressive histology non-Hodgkin’s lymphoma.

Research Question(s)

  1. What treatment provides the optimum disease control and survival in older patients (at least 60 years of age) with newly diagnosed, advanced-stage, aggressive histology lymphoma?
  2. What are the toxicities associated with these treatments?
  3. What are the roles of granulocyte-colony stimulating factor or granulocyte macrophage-colony stimulating factor in combination with chemotherapy in these patients?